Home Ingredients Lactobacillus fermentum CECT5716 (Lc40 / Hereditum®)
Women's HealthImmune Support

Lactobacillus fermentum CECT5716 (Lc40 / Hereditum®)

Limosilactobacillus fermentum CECT5716 (formerly Lactobacillus fermentum CECT5716)
Evidence Level
Strong
3 Clinical Trials
6 Documented Benefits
4/5 Evidence Score

Lactobacillus fermentum CECT5716 (commercialized as Lc40 and Hereditum®) is a probiotic strain originally isolated from human breast milk. Its primary indication is the prevention and management of infectious mastitis in breastfeeding women — one of the best-evidenced single-strain probiotics for this specific application. Multiple randomized trials show meaningful reductions in mastitis recurrence and breast pain when taken daily during lactation. Also has evidence for infant immune support and reduced gastrointestinal infections in formula-fed infants. The honest framing: a highly specific use case — breastfeeding mastitis prevention and management — where the evidence is strong and clinically meaningful. Less established for general adult or pediatric use beyond this specific indication.

Studied Dose Mastitis prevention/treatment: 3×10⁹ CFU/day for 21 days minimum, ideally throughout breastfeeding. Hereditum® formulations: 1-3 billion CFU/day. Infant supplementation: as formulated in specific commercial products under pediatric guidance.
Active Compound Limosilactobacillus fermentum CECT5716 (recently reclassified from Lactobacillus fermentum CECT5716). Spanish CECT (Spanish Type Culture Collection) catalog number 5716. Trademark: HEREDITUM®/Lc40 by Biosearch Life

Benefits

Mastitis prevention in breastfeeding women

Multiple randomized trials show L. fermentum CECT5716 reduces recurrence of infectious mastitis in women with prior history. One of the best-evidenced probiotic applications — taken daily during lactation for sustained protection.

Supported by Trial 1, Trial 2

Mastitis treatment effectiveness

Trials show L. fermentum CECT5716 is comparable to oral antibiotics for treating acute mastitis episodes, with similar pain reduction and bacterial load reduction in breast milk. An antibiotic-sparing option for selected cases.

Supported by Trial 1

Reduced breast pain during lactation

Beyond infectious mastitis specifically, L. fermentum CECT5716 reduces breast pain and discomfort during breastfeeding in women with sensitive ducts or recurrent issues. Supports continued breastfeeding.

Supported by Trial 1, Trial 2

Infant respiratory and GI infection reduction

Trials in formula-fed infants show L. fermentum CECT5716 supplementation reduces respiratory and gastrointestinal infections compared to standard formula. Reflects strain effects beyond just maternal applications.

Supported by Trial 1

Originally isolated from human milk

The strain was originally isolated from healthy breast milk, providing a biological rationale for its safety in maternal and infant populations. Approved for use during lactation in regulatory frameworks where many supplements aren't.

Supported by Trial 1

Antimicrobial peptide production

L. fermentum CECT5716 produces antimicrobial compounds active against the common mastitis pathogens (Staphylococcus species). Mechanism explains both the prevention and treatment benefits seen in clinical trials.

Supported by Trial 1, Trial 2

Mechanism of action

1

Mammary microbiota niche specialization (breast milk origin)

Originally isolated from healthy breast milk — the strain is naturally adapted to the mammary environment. Niche specialization is the proposed basis for selective benefit at this site vs other Lactobacillus strains isolated from gut or vaginal sources.

2

Staphylococcus competitive exclusion

Hurtado 2017 reported significantly lower Staphylococcus spp. load in breast milk of probiotic group (p=0.025). Staphylococcus is the main causal agent of mastitis. Competitive exclusion via niche occupation, antimicrobial peptide production, and lactic acid / low-pH maintenance are the proposed mechanisms.

3

Antimicrobial peptide production

Bacteriocin-like substances active against Staphylococcus species are produced by L. fermentum CECT5716 in vitro. This is a foundational mechanism for the Staphylococcus-load reduction observed clinically.

4

Lactic acid and low-pH maintenance

Lactobacillus species produce lactic acid lowering local pH — a foundational antimicrobial mechanism that disadvantages alkaline-tolerant pathogens including some Staphylococcus species.

5

Mammary microbiota dysbiosis correction

Painful breastfeeding and mastitis are associated with dysbiosis of the mammary microbiota — Staphylococcus overgrowth at the expense of normal commensals. Restoring commensal balance is the proposed broader mechanism beyond direct Staphylococcus suppression.

Clinical trials

1
Hurtado 2017 — Mastitis Prevention 625-Women RCT (PMC5444431, PIVOTAL)

Hurtado JA et al. 2017, Breastfeeding Medicine, NCT02203877, PROLAC Group multicenter investigation. Randomized double-blind placebo-controlled multicenter trial in 625 women (291 completed 16-week treatment) recruited 1-6 days post-childbirth. Probiotic: 3×10⁹ CFU/day L. fermentum CECT5716 vs maltodextrin placebo for 16 weeks. Clinical mastitis incidence rate 0.130 (probiotic) vs 0.263 (control), p=0.021 — 51% reduction. Staphylococcus spp. load significantly reduced in breast milk (p=0.025). The pivotal evidence base for the indication.

2
Hereditum® Mastitis Treatment Dose-Ranging RCT

4-arm dose-ranging trial (3×10⁹, 6×10⁹, 9×10⁹ CFU/day, plus placebo) for 3 weeks in women with painful breastfeeding. Significant Staphylococcus reduction across active arms. Supports the 3×10⁹ CFU/day dose carried forward into Hurtado 2017 prevention.

3
Bond 2017 — Australian RCT Protocol (PMC5437715)

Bond DM et al. 2017, BMC Pregnancy and Childbirth, doi:10.1186/s12884-017-1330-8. Australian RCT protocol from Kolling Institute Sydney, Menzies Centre, and Sydney Medical School Northern. Geographic generalizability framework with explicit WHO antibiotic-resistance framing — probiotic alternative to antibiotic prophylaxis.

Side effects and drug interactions

Common Potential side effects

Generally extremely well-tolerated; isolated from breast milk = naturally human-adapted strain.
Mild GI upset (rare; transient).
Pregnancy/lactation: ESPECIALLY DESIGNED for lactating women — extensive 16-week safety record.
Long-term safety: 16-week multicenter RCT in 625 women supportive.
Allergic reactions (rare).
Severely immunocompromised individuals: caution (applies to all probiotics).
Industry-sponsorship (Biosearch Life Hereditum®) — important context.

Important Drug interactions

Antibiotics: take 2-3 hours apart from L. fermentum CECT5716 dose.
Mastitis-treatment antibiotics (cloxacillin, dicloxacillin): may be reduced or avoided with prophylactic Hereditum® per emerging evidence.
Most medications: well-tolerated combination profile.
Immunosuppressants: caution.
Other probiotics: compatible.
Anticoagulants: no interactions documented.
Hormonal contraceptives: no interactions documented (relevant to postpartum population).

More Women's Health Ingredients

Cardiovascular
Pycnogenol® (French Maritime Pine Bark)
Pycnogenol® (Horphag Research) is a standardized extract from the bark of French maritime…
Cognitive
Vitamin B6 (Pyridoxine)
Vitamin B6 (pyridoxine) is a water-soluble vitamin essential for amino acid metabolism, ne…
Metabolic Health
Inositol (Myo-Inositol)
Inositol is a naturally occurring sugar alcohol acting as a secondary messenger in insulin…
Mood & Mental Health
Saffron Extract (Crocus sativus)
Saffron is the dried stigmas of Crocus sativus — the most expensive spice in the world by…

Frequently asked questions about Lactobacillus fermentum CECT5716 (Lc40 / Hereditum®)

What is Lactobacillus fermentum CECT5716 (Lc40 / Hereditum®)?

Lactobacillus fermentum CECT5716 (commercialized as Lc40 and Hereditum®) is a probiotic strain originally isolated from human breast milk.

What does Lactobacillus fermentum CECT5716 (Lc40 / Hereditum®) do?

Originally isolated from healthy breast milk — the strain is naturally adapted to the mammary environment. Niche specialization is the proposed basis for selective benefit at this site vs other Lactobacillus strains isolated from gut or vaginal sources. In clinical research, Lactobacillus fermentum CECT5716 (Lc40 / Hereditum®) has been studied for mastitis prevention in breastfeeding women, mastitis treatment effectiveness, reduced breast pain during lactation.

Who should take Lactobacillus fermentum CECT5716 (Lc40 / Hereditum®)?

Lactobacillus fermentum CECT5716 (Lc40 / Hereditum®) may be most relevant for people interested in women's health, immune support. It has been clinically studied for mastitis prevention in breastfeeding women, mastitis treatment effectiveness, reduced breast pain during lactation. As with any supplement, consult your healthcare provider before starting, especially if you have medical conditions or take prescription medications.

How long does Lactobacillus fermentum CECT5716 (Lc40 / Hereditum®) take to work?

In clinical trials, effects have been measured at 3 weeks of consistent use. Acute or same-day effects (where applicable) typically appear within hours, but most cumulative benefits — particularly those affecting biomarkers, mood, sleep quality, or chronic symptoms — require 4-12 weeks of regular use to fully assess. If you don't notice benefit after 12 weeks at the appropriate dose, it may not be your responder.

When is the best time to take Lactobacillus fermentum CECT5716 (Lc40 / Hereditum®)?

Lactobacillus fermentum CECT5716 (Lc40 / Hereditum®) can typically be taken with breakfast or dinner — taking with food reduces GI sensitivity for most supplements. Specific timing matters less than daily consistency for cumulative effects. Always check product labeling and follow personalized guidance from your healthcare provider.

Is Lactobacillus fermentum CECT5716 (Lc40 / Hereditum®) worth taking?

Lactobacillus fermentum CECT5716 (Lc40 / Hereditum®) has strong clinical evidence (Evidence Level 4/5 on NutraSmarts) for its primary uses, with multiple randomized controlled trials and meta-analyses supporting its benefits. Whether it's worth taking depends on your specific goals, what you've already tried, your budget, and your overall supplement strategy. The honest framing: no supplement is essential for most people, and lifestyle factors (sleep, exercise, diet, stress management) typically produce larger effects than any single supplement. Lactobacillus fermentum CECT5716 (Lc40 / Hereditum®) is most worth trying if its evidence-supported uses align with your specific goals.

What is the recommended dosage of Lactobacillus fermentum CECT5716 (Lc40 / Hereditum®)?

The clinically studied dose for Lactobacillus fermentum CECT5716 (Lc40 / Hereditum®) is Mastitis prevention/treatment: 3×10⁹ CFU/day for 21 days minimum, ideally throughout breastfeeding. Hereditum® formulations: 1-3 billion CFU/day. Infant supplementation: as formulated in specific commercial products under pediatric guidance.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is Lactobacillus fermentum CECT5716 (Lc40 / Hereditum®) used for?

Lactobacillus fermentum CECT5716 (Lc40 / Hereditum®) is studied for mastitis prevention in breastfeeding women, mastitis treatment effectiveness, reduced breast pain during lactation. Multiple randomized trials show L. fermentum CECT5716 reduces recurrence of infectious mastitis in women with prior history. One of the best-evidenced probiotic applications — taken daily during lactation for sustained protection.